Association of Chemoradiation, Trimodality Therapy, or Salvage Resection with Survival in Stage II-III Esophageal Squamous Cell Carcinoma.

IF 4.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Sara Sakowitz, Syed Shahyan Bakhtiyar, Saad Mallick, Yas Sanaiha, Ann Raldow, Peyman Benharash, Jane Yanagawa
{"title":"Association of Chemoradiation, Trimodality Therapy, or Salvage Resection with Survival in Stage II-III Esophageal Squamous Cell Carcinoma.","authors":"Sara Sakowitz, Syed Shahyan Bakhtiyar, Saad Mallick, Yas Sanaiha, Ann Raldow, Peyman Benharash, Jane Yanagawa","doi":"10.1016/j.jtcvs.2025.03.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Esophageal squamous cell carcinoma(ESCC) remains highly lethal and often under-treated. With conflicting evidence regarding the additional benefit of surgical resection to chemoradiation, many patients with locoregionally-advanced disease may receive chemoradiation and then undergo evaluation for progression before esophagectomy. We hypothesized that trimodality therapy or salvage resection would be linked with superior overall survival, relative to definitive chemoradiation.</p><p><strong>Methods: </strong>This retrospective analysis of the 2004-2021 National Cancer Database identified all clinically-staged II-III ESCC patients≥18years. Patients undergoing chemotherapy and ≥41.4 Grays of radiation across 28 fractions, followed by esophagectomy <90 days were considered the trimodality cohort, while those undergoing resection ≥90 days were classified as salvage. Patients receiving definitive chemoradiation were categorized as definitive CRT.</p><p><strong>Results: </strong>Of 3,786 patients, 912 (24%) underwent trimodality therapy, 173 (5%) chemoradiation followed by salvage resection, and 2,701 (71%) definitive CRT. Following risk-adjustment and relative to definitive CRT, trimodality was linked with greater survival at 1 (HR 0.45, CI 0.34-0.59) and 5 years (HR 0.57, CI 0.49-0.66), as was salvage (1 year: HR 0.38, CI 0.22-0.69; 5 year: HR 0.54, CI 0.40-0.73). Upon RMST analysis, trimodality demonstrated a 9.17 month (CI 6.40-11.94) incremental increase in overall survival time over 5 years, while salvage was linked with a 10.03 month (CI 4.04-16.03) increase in survival time, compared to definitive CRT.</p><p><strong>Conclusions: </strong>Surgical resection following chemoradiation confers survival benefit and should be considered a mainstay in the management of locoregionally-advanced ESCC. Yet, with comparable outcomes across trimodality and salvage approaches, organ preservation may be appropriate, for select patients.</p>","PeriodicalId":49975,"journal":{"name":"Journal of Thoracic and Cardiovascular Surgery","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic and Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtcvs.2025.03.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Esophageal squamous cell carcinoma(ESCC) remains highly lethal and often under-treated. With conflicting evidence regarding the additional benefit of surgical resection to chemoradiation, many patients with locoregionally-advanced disease may receive chemoradiation and then undergo evaluation for progression before esophagectomy. We hypothesized that trimodality therapy or salvage resection would be linked with superior overall survival, relative to definitive chemoradiation.

Methods: This retrospective analysis of the 2004-2021 National Cancer Database identified all clinically-staged II-III ESCC patients≥18years. Patients undergoing chemotherapy and ≥41.4 Grays of radiation across 28 fractions, followed by esophagectomy <90 days were considered the trimodality cohort, while those undergoing resection ≥90 days were classified as salvage. Patients receiving definitive chemoradiation were categorized as definitive CRT.

Results: Of 3,786 patients, 912 (24%) underwent trimodality therapy, 173 (5%) chemoradiation followed by salvage resection, and 2,701 (71%) definitive CRT. Following risk-adjustment and relative to definitive CRT, trimodality was linked with greater survival at 1 (HR 0.45, CI 0.34-0.59) and 5 years (HR 0.57, CI 0.49-0.66), as was salvage (1 year: HR 0.38, CI 0.22-0.69; 5 year: HR 0.54, CI 0.40-0.73). Upon RMST analysis, trimodality demonstrated a 9.17 month (CI 6.40-11.94) incremental increase in overall survival time over 5 years, while salvage was linked with a 10.03 month (CI 4.04-16.03) increase in survival time, compared to definitive CRT.

Conclusions: Surgical resection following chemoradiation confers survival benefit and should be considered a mainstay in the management of locoregionally-advanced ESCC. Yet, with comparable outcomes across trimodality and salvage approaches, organ preservation may be appropriate, for select patients.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.20
自引率
10.00%
发文量
1079
审稿时长
68 days
期刊介绍: The Journal of Thoracic and Cardiovascular Surgery presents original, peer-reviewed articles on diseases of the heart, great vessels, lungs and thorax with emphasis on surgical interventions. An official publication of The American Association for Thoracic Surgery and The Western Thoracic Surgical Association, the Journal focuses on techniques and developments in acquired cardiac surgery, congenital cardiac repair, thoracic procedures, heart and lung transplantation, mechanical circulatory support and other procedures.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信